Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing unique epigenetic and genetic profiles. U-CLL C1 is enriched for ATM deletions ...
In chronic lymphocytic leukemia (CLL), a neoplastic disease characterized by highly variable clinical courses [1,2,3,4], the mutational status of the heavy chain variable region of the immunoglobulin ...
Suchitra Sundaram, MD, reviews new data on CLL treatments presented at ASH 2024, highlighting exciting possibilities for future patient care. She recounts the case of a 75-year-old man with worsening ...
Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...
The study included 639 patients, 79.8% of whom had previously received covalent BTK inhibitors.
SAN DIEGO — Treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in combination with venetoclax was associated with improved progression-free survival compared with ...
Calquence and Venclexta, with or without Gazyva, improved PFS in untreated CLL patients compared to standard chemoimmunotherapy. The AMPLIFY trial showed reduced disease progression risk with the ...
EHA June 2026 guidelines endorse time-limited first-line CLL therapy based on TP53 and IGHV, informed by CLL17 showing fixed-duration targeted therapy noninferior to continuous ibrutinib. MRD-guided ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results